The British journal of dermatology
-
Randomized Controlled Trial Multicenter Study
A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.
Hidradenitis suppurativa (HS) has an impact on patients' quality of life. Treatment of HS is generally unsatisfactory, thus new treatments are needed. ⋯ A significant reduction in HS severity was gained after 6 weeks. No long-term curative effect was uniformly seen.
-
Randomized Controlled Trial
Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study.
CHAMPION was a phase III trial that compared adalimumab with methotrexate and placebo for chronic plaque psoriasis. ⋯ Nearly all week 16 PASI 75 responders in CHAMPION achieved a PASI 50 response at week 8 or 12, with maximum methotrexate dosages of 15 or 20 mg per week, respectively. Week 12 may be an appropriate time to discontinue methotrexate treatment in patients who are not achieving good responses.